Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company pioneering novel antibiotics for resistant Gram-positive infections. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and regulatory progress.
Access timely reports on clinical trial developments, including Phase 3 preparations for ibezapolstat targeting C. difficile infections. Stay informed about patent grants, research collaborations, and financial disclosures that demonstrate ACXP's commitment to addressing antimicrobial resistance through targeted DNA polymerase IIIC inhibition technology.
Our curated collection features press releases detailing milestone achievements, peer-reviewed study publications, and strategic partnership announcements. All content is verified for accuracy and relevance to support informed decision-making in the evolving antibiotic development landscape.
Bookmark this page for direct access to Acurx's latest progress in creating narrow-spectrum therapies that combat priority pathogens while preserving microbiome balance – a critical differentiator in modern infectious disease treatment.
Acurx Pharmaceuticals (Nasdaq: ACXP) announced on Nov 18, 2025 that Health~Holland awarded a research grant of approximately $375,000 to Leiden University Medical Center and, via a three-party consortium, to Acurx to fund POLSTOP4MDRO.
The project will extend prior LUMC–Acurx structural biology work that produced three PolC structures (apo, with ibezapolstat and with ACX-801) and kinetic data versus MRSA, VRE and PRSP. The new work aims to generate the first 3D structure of PolC from MRSA bound to an Acurx inhibitor and to study conservation of mode-of-action and resistance across Gram-positive multidrug-resistant pathogens. The release notes ibezapolstat is Phase 3–ready and mentions Acurx's preclinical program for inhalational anthrax.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported third-quarter 2025 results and operational updates on Nov 12, 2025. Key items: a 1-for-20 reverse stock split on Aug 4, 2025 restored Nasdaq minimum bid-price compliance on Aug 26, 2025 and the company now meets Nasdaq equity thresholds. The Australian patent for DNA polymerase IIIC inhibitors was granted in Sep 2025, joining prior U.S., Israeli, Japanese and Indian patents covering ACX-375C.
Cash totaled $5.9M at Sep 30, 2025; recent financings raised ~$1.7M (equity line) plus ~$1.4M from warrant exercises. Q3 R&D and G&A declined versus prior year; net loss was $2.0M for Q3 2025.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported publication in Nature Communications demonstrating for the first time structural evidence of its DNA pol IIIC inhibitor, ibezapolstat, bound to its bacterial target.
The release highlights Phase 2 clinical results for ibezapolstat in C. difficile infection: 96% initial cure and no recurrence, and states the program is Phase 3 ready in the U.S. and EU. Ibezapolstat previously received FDA QIDP and Fast-Track designations and EMA SME designation. Acurx also describes a preclinical oral pipeline for ABSSSI and HAP/VAP and parallel planning for an inhaled anthrax program.
Acurx Pharmaceuticals (NASDAQ: ACXP) presented new data at IDWeek 2025 (Oct 19-22, 2025) showing its Phase 3-ready DNA pol IIIC inhibitor ibezapolstat (IBZ) exhibits selective antibacterial activity in the gut that spares bile acid-metabolizing bacteria, a profile linked to IBZ's anti-recurrence effect in C. difficile infection where no patient cured in Phase 2 experienced recurrence.
New preclinical colonic microbiome data in a mouse model suggest representative DNA pol IIIC inhibitor compounds may share this microbiome-sparing class effect compared with linezolid. Ibezapolstat has FDA QIDP and Fast-Track designation; Acurx's preclinical candidates are QIDP/Fast-Track eligible for systemic Gram-positive infections.
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 a.m. ET before U.S. markets open.
David P. Luci, President and CEO, and Robert G. Shawah, CFO, will host a conference call to review the results and provide a business update. Toll-free U.S. dial-in is 1-877-790-1503 with Conference ID 13756868; international participant numbers are available via the company’s conferencing link.
Acurx (NASDAQ: ACXP) announced an Australian patent grant for DNA Polymerase IIIC inhibitors, adding to its global intellectual property that already includes three U.S. patents and patents in Israel, Japan and India.
The patent covers compositions of matter tied to the ACX-375C program. Management noted the lead DNA pol IIIC inhibitor is Phase 3-ready for oral C. difficile treatment, while new preclinical compounds are systemically absorbed for potential oral and parenteral use across indications including ABSSSI (MRSA), CABP, HABP/VABP, bacteremia/sepsis, endocarditis, bone/joint infections, prosthetic joint infections and inhalational anthrax.
Acurx Pharmaceuticals (NASDAQ:ACXP) has received a positive opinion from the European Medicines Agency's (EMA) Paediatric Committee (PDCO) on its Pediatric Investigation Plan (PIP) for ibezapolstat in treating children with C. difficile infection (CDI). This marks a significant regulatory milestone as the company prepares for Phase 3 clinical trials.
The company has already secured FDA QIDP and Fast-Track Designation, along with EMA's SME designation. Both the FDA and EMA are aligned with Acurx's clinical trial program for adults, with clear regulatory pathways established for EU MAA and U.S. NDA submissions. The development addresses a critical need, as CDI affects 20,000 children annually, with a 20-30% recurrence rate.
Upon successful completion, ibezapolstat could receive 11 years of marketing exclusivity in Europe, including an additional year on top of the standard 10-year period for new antibiotics.
[ "Positive EMA opinion received for pediatric investigation plan (PIP)", "FDA QIDP and Fast-Track Designation already secured", "Potential for 11 years of marketing exclusivity in Europe", "Clear regulatory pathway established with both FDA and EMA", "Addresses significant unmet need in pediatric CDI treatment" ]Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company focused on developing novel antibiotics, has successfully regained compliance with Nasdaq's listing requirements. The company has met two critical criteria: maintaining a minimum bid price of $1.00 per share and achieving the minimum stockholders' equity threshold of $2.5 million.
This development ensures ACXP's continued listing and trading on the Nasdaq Stock Market, marking a significant milestone for the company's market presence and accessibility to investors.
Acurx Pharmaceuticals (NASDAQ:ACXP), a late-stage biopharmaceutical company, reported its Q2 2025 financial results and business updates. The company ended Q2 with $6.1 million in cash, up from $3.7 million in December 2024. Key developments include securing an Indian patent for DNA polymerase IIIC inhibitors and establishing a $12 million equity line of credit with Lincoln Park Capital.
The company reported a reduced net loss of $2.2 million ($1.89 per share) in Q2 2025, compared to $4.1 million in Q2 2024. R&D expenses decreased to $0.5 million from $1.8 million year-over-year, while G&A expenses reduced to $1.7 million from $2.3 million. In August, ACXP implemented a 1-for-20 reverse stock split to maintain Nasdaq listing compliance.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced a 1-for-20 reverse stock split effective August 4, 2025, at 4:01 p.m. ET. The company's stock will begin trading on a split-adjusted basis on August 5, 2025, under the same ticker "ACXP" but with a new CUSIP number (00510M 203).
The reverse split will reduce outstanding shares from approximately 30.7 million to 1.5 million. The move aims to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement. Stockholders will receive cash payments for fractional shares based on the closing price on August 1, 2025.
Proportional adjustments will be made to stock options, warrants, and shares under incentive plans. Most shareholders won't need to take action, as positions will be automatically adjusted through their brokers.
FAQ
What is the current stock price of Acurx Pharmaceuticals (ACXP)?
What is the market cap of Acurx Pharmaceuticals (ACXP)?
